Selection and characterisation of bioreceptors to develop nanoparticle-based lateral-flow immunoassays in the context of the SARS-CoV-2 outbreak

Lab Chip. 2022 Aug 9;22(16):2938-2943. doi: 10.1039/d2lc00486k.

Abstract

This manuscript aims at raising the attention of the scientific community to the need for better characterised bioreceptors for fast development of point-of-care diagnostic devices able to support mass frequency testing. Particularly, we present the difficulties encountered in finding suitable antibodies for the development of a lateral flow assay for detecting the nucleoprotein of SARS-CoV-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral
  • COVID-19* / diagnosis
  • Disease Outbreaks
  • Humans
  • Immunoassay
  • Nanoparticles*
  • SARS-CoV-2
  • Sensitivity and Specificity

Substances

  • Antibodies, Viral